



**EUROPEAN COMMISSION**

Directorate-General for Internal Market, Industry, Entrepreneurship and SMEs

Innovation and Advanced Manufacturing  
The Director

Brussels,  
GROW/F5 - [REDACTED]  
grow.ddg1.f.5(2018)1422531

Mr Alexander Natz  
Secretary-General  
EUCOPE  
Rue Marie de Bourgogne 58  
1000 Bruxelles  
(email : [natz@eucope.org](mailto:natz@eucope.org))

Dear Mr Natz,

Thank you for your letter of 16 February 2018 to Commissioner Bieńkowska, in which you reiterate your concerns of 24 January regarding the on-going reflections of the Commission relating to *Supplementary Protection Certificates*. The Commissioner has asked me to respond on her behalf.

As our Director-General, Lowri Evans, wrote to you on 7 March, no decision has yet been taken regarding a Commission initiative in this respect.

In line with our Better Regulation and impact assessment rules, the Commission services are analysing a broad range of sources of information and evidence, not limited to the CRA study, but including a number of originators-sponsored studies such as the OHE-EFPIA study or the one prepared by Pugatch Consilium.

Please rest assured that we are treating all parts of the pharmaceutical industry equally, and any additional input from small and mid-sized companies, including EUCOPE members, will be duly considered.

Yours sincerely,

*e-signed*  
Slawomir Tokarski